Clinical trial · Interventional
Molecular Profiling of Exosomes in Tumor-draining Vein of Early-staged Lung Cancer
Analyse du Profil moléculaire Des Exosomes de la Veine Pulmonaire Dans le Cancer Bronchique de Stade précoce
NCT04939324CI-TRIAL-00116049ExOnSite-ProcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an observational prospective single-center study of 30 patients operated for early-staged non-small cell lung cancer. The main aim is the analysis of molecular profiling of exosome with a sample in tumor-draining vein in order to identify prognostic molecular characteristics associated with cancer recurrence after surgery.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Exosomes | — | UNRESOLVED | — |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood samples at 2 sites: peripheral vein and tumor-draining vein | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Blood samples at 2 sites: peripheral vein and tumor-draining vein
- description
- D0: surgery (inclusion): oncological lung resection * Blood samples at 2 sites: peripheral vein and tumor-draining vein * Resected tumor analysis Standard clinical and radiological follow-up during 2 years (medical consultation or phone call)
- interventionNames
- Biological: Blood samples at 2 sites: peripheral vein and tumor-draining vein
Primary outcomes (1)
- measure
- Evaluate size distribution, concentration and molecular profiling of pulmonary vein exosomes at inclusion
- timeFrame
- 36 months
- description
- Concentration of extracellular vesicule (million of particule/mL of blood)
Secondary outcomes (4)
- measure
- Size distribution, molecular profiling of peripheral vein exosome sat inclusion
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: \- Surgical non-small cell lung cancer with pure solid nodule or part-solid ground glass nodule on CT-scan Exclusion Criteria: * Pure ground glass nodule, * Neoadjuvant therapy, * Second cancer or cancer in the 5 years, * Pregnancy, * Patients \<18 years-old, * Tutorship
References
Publications (1)
- DERIVEDTricard J, Durand S, Rovini A, Gateau A, Negroni L, Chaunavel A, Chermat A, Jauberteau MO, Conti M, Akil H, Lalloue F. New proteomic signature in circulating extracellular vesicles from tumor-draining and peripheral veins of patients with lung adenocarcinoma. Cancer Cell Int. 2026 Apr 1;26(1):192. doi: 10.1186/s12935-026-04264-9. PMID 41923119